Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma(NewEC Study)

CompletedOBSERVATIONAL
Enrollment

423

Participants

Timeline

Start Date

November 14, 2018

Primary Completion Date

December 1, 2019

Study Completion Date

December 1, 2019

Conditions
Radiotherapy Side EffectChemotherapy EffectOesophageal CarcinomaEffect of DrugsSafety Issues
Interventions
COMBINATION_PRODUCT

Neoadjuvant chemoradiotherapy

In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.

PROCEDURE

Oesophagectomy

Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic,and the appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.

DRUG

Neoadjuvant chemotherapy

In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.

Trial Locations (3)

510000

Guangdong Provincial People's Hospital, Guangzhou

Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou

01748

Massachusetts General Hospital of Harvard Medical School, Boston

All Listed Sponsors
collaborator

Guangdong Provincial People's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT04027543 - Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma(NewEC Study) | Biotech Hunter | Biotech Hunter